Innovation to Beauty and Health

R&D center

Hugel Biotech Research Center in pursuit of healthy beauty

This is where Hugel’s future lies. Here, top researchers from around the world strives to develop and implement newest technologies, with focus on aesthetics and therapeutics.

R&D Status

R&D Status
Next-Generation Botulinum Toxin
Development of an advanced formula for the existing botulinum toxin product, and a next-generation botulinum toxin with new indications
Hyaluronic Acid Filler
Development of multi-functional fillers to maximize the effects of hyaluronic acid fillers currently available in the market
Prevention and Treatment of Curable Hypertrophic Scars
Development of new pharmaceuticals using RNAi (RNA interference) molecules. Currently, preclinical trials are underway and with successful development, HUGEL will be the first company in Korea to launch an RNAi pharmaceutical.
Botulinum Toxin
Clinical testing for the treatment of blepharospasm glabellar lines, pediatric cerebral palsy, and post- stroke upper limb spasticity. Hugel will conduct R&D to generate diverse indications approved for botulinum toxin and will also apply advanced technology to seek methods to maximize effects of neurotoxin treatment.
Transdermal Delivery System
Development of micro-needle and transcellular permeability carrier system for effective delivery of medication through the skin

About the Hugel Biotech Research Center


  • - Pharmaceutical & Biological Research Dept.
  • - Analytical Research Dept.
R&D Planning
  • - R&D Planning Team
  • - Process Development Team
Overseas RA Department
  • - Overseas RA Team
  • - PV Team